Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Share-based Compensation (2016 - 2025)

Heron Therapeutics' Share-based Compensation history spans 14 years, with the latest figure at $2.2 million for Q4 2025.

  • For Q4 2025, Share-based Compensation fell 5.05% year-over-year to $2.2 million; the TTM value through Dec 2025 reached $10.3 million, down 20.24%, while the annual FY2025 figure was $10.3 million, 20.24% down from the prior year.
  • Share-based Compensation reached $2.2 million in Q4 2025 per HRTX's latest filing, down from $2.9 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $13.9 million in Q2 2023 to a low of $2.2 million in Q4 2025.
  • Average Share-based Compensation over 5 years is $7.3 million, with a median of $7.3 million recorded in 2023.
  • Peak YoY movement for Share-based Compensation: skyrocketed 34.26% in 2023, then tumbled 67.12% in 2024.
  • A 5-year view of Share-based Compensation shows it stood at $12.9 million in 2021, then decreased by 18.42% to $10.5 million in 2022, then tumbled by 58.87% to $4.3 million in 2023, then plummeted by 46.92% to $2.3 million in 2024, then dropped by 5.05% to $2.2 million in 2025.
  • Per Business Quant, the three most recent readings for HRTX's Share-based Compensation are $2.2 million (Q4 2025), $2.9 million (Q3 2025), and $2.8 million (Q2 2025).